Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 19, 2020 08:00 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals, Inc. Announces Stockholder Approval of Proposals Required for Merger Transaction with Qualigen, Inc.

LOS ANGELES, May 19, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”, “Ritter” or the “Company”), announced today that, based upon the final vote count...
March 31, 2020 17:27 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2019

Definitive merger agreement with Qualigen, Inc. announced in January 2020 LOS ANGELES, March 31, 2020 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals”,...
June 20, 2019 09:15 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Provides Phase 3 Liberatus Clinical Trial and Regulatory Update

LOS ANGELES, June 20, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of innovative therapeutic products that modulate...
May 07, 2019 09:15 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Completes Dosing of Last Patient in Pivotal 557-Subject Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout on Target for early Q4 2019 LOS ANGELES, May 07, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
March 05, 2019 08:30 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Completes Enrollment in Pivotal Phase 3 Clinical Trial of RP-G28 in Patients with Lactose Intolerance

Top-line Data Readout Expected in early Q4 2019 LOS ANGELES, March 05, 2019 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a...
August 14, 2018 16:15 ET | Source: Ritter Pharmaceuticals, Inc.

Ritter Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2018 and Recent Progress

LOS ANGELES, Aug. 14, 2018 (GLOBE NEWSWIRE) -- Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter Pharmaceuticals” or the “Company”), a developer of novel therapeutic products that modulate the...